Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

High-Grade B-Cell Lymphomas with MYC and BCL2 Translocations Lack Tumor-Associated Macrophages and PD-L1 Expression: A Possible Noninflamed Subgroup

Marie Fredslund Breinholt, MD, Douglas NP de Oliveira, PhD, Tobias Wirenfeldt Klausen, M.S., Lone Schejbel, PhD, Anne Ortved Gang, MDPhD, Mette Ø Pedersen, MDPhD, Mette Vestergaard Elbæk, MD, Erik Clasen-Linde, MD, Signe Ledou Nielsen, MD, Helle Knudsen, MD, Estrid Hogdall, PhD DMSci, Peter H. Norgaard, MDPhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134411

Published: 2020

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

Vibe Skov, PhD, Katrine LM Schmidt, Kasper Mønsted Pedersen, MD, Bettina Hansen, Tobias Wirenfeldt Klausen, M.S., Torben A Kruse, Mads Thomassen, PhD, Lasse Kjær, PhD, Christina Ellervik, Associate Professor, MD PhD, Morten Holmstrøm, MD, Bjørn Nexø, Hans Carl Hasselbalch, Professor, dr.MD, Magdalena J Laska

Blood (2018) 132 (Supplement 1): 5488.

https://doi.org/10.1182/blood-2018-99-118080

Published: 2018

Journal Articles

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Henrik Gregersen, MD, Niels Abildgaard, MD, Trung Hieu Do, MD, Ida Bruun Kristensen, MD, Ulf Christian Frølund, MD, Niels Frost Andersen, MD, Lene Kongsgaard Nielsen, MD, Christen Lykkegaard Andersen, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD

Blood (2017) 130 (Supplement 1): 3129.

https://doi.org/10.1182/blood.V130.Suppl_1.3129.3129

Published: 2017

Journal Articles

Stratification By MYC Protein Expression Level Improves the Prognostic Impact of MYC Translocation in Patients with Large B-Cell Lymphoma

Mette Ø Pedersen, MD, Anne Ortved Gang, MDPhD, Erik Clasen-Linde, MD, Marie Fredslund Breinholt, MD, Helle Knudsen, MD, Signe Ledou Nielsen, MD, Tim Svenstrup Poulsen, PhD, Tobias Wirenfeldt Klausen, M.S., Estrid Hogdall, PhD, Peter H. Norgaard, MDPhD

Blood (2017) 130 (Supplement 1): 1484.

https://doi.org/10.1182/blood.V130.Suppl_1.1484.1484

Published: 2017

NARROW

High-Grade B-Cell Lymphomas with MYC and BCL2 Translocations Lack Tumor-Associated Macrophages and PD-L1 Expression: A Possible Noninflamed Subgroup

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Stratification By MYC Protein Expression Level Improves the Prognostic Impact of MYC Translocation in Patients with Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

High-Grade B-Cell Lymphomas with MYC and BCL2 Translocations Lack Tumor-Associated Macrophages and PD-L1 Expression: A Possible Noninflamed Subgroup

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Stratification By MYC Protein Expression Level Improves the Prognostic Impact of MYC Translocation in Patients with Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only